A Phase I Study to Evaluate the Safety and Tolerability of GENA-104A16 (Anti-contactin4 [CNTN4] Monoclonal Antibody [mAb]) in Patients With Advanced Solid Tumors
This is a first in human phase I , open label study to evaluate the safety and tolerability of GENA 104A16 administered as a single agent by intravenous (IV) once every 2 weeks ( q2w (1 cycle = 2 weeks) in patients with advanced solid tumors, for who no standard therapy exists, or standard therapy has failed.
100 项与 GENA-104A16 相关的临床结果
100 项与 GENA-104A16 相关的转化医学
100 项与 GENA-104A16 相关的专利(医药)
100 项与 GENA-104A16 相关的药物交易